Famous Patents
In 1879, Auguste Bartholdi received design patent number 11,023 titled "Design for a Statue". It was for the Statue of Liberty.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8017609 | Method for the prevention of thromboembolic disorders A method for the prevention of thrombotic, embolic and/or hemorrhagic disorders, such as cerebral infarction (stroke) or myocardial infarction, by administering levosimendan or its metabolite (II) or any of their pharmaceutically acceptable salts to a mammal in need... | 09/13/2011 |
| 7932415 | Process for manufacturing entacapone New processes for manufacturing entacapone are provided. ... | 04/26/2011 |
| 7863311 | Transmucosal veterinary composition comprising detomidine The present invention relates to a veterinary composition in a semisolid form adapted for transmucosal administration for providing sedation and analgesia in large animals such as horses and cattle. The semisolid transmucosal composition of the invention comprises d... | 01/04/2011 |
| 7759496 | Imidazole derivatives having affinity for alpha 2 receptors activity Novel prodrugs of MPV-2426, methods for preparing said prodrug forms, pharmaceutical compositions containing such prodrug forms, and methods for using the prodrug forms. A compound of general formula (I), or pharmaceuticall... | 07/20/2010 |
| 7728147 | Detomidine hydrochloride crystallization method A method of isolating detomidine (I) hydrochloride as a crystalline salt is provided. The method comprises hydrogenating in the presence of a catalyst of compound of formula (II) in aqueous solution comprising hydrochloric acid, concentrating the solution by distill... | 06/01/2010 |
| 7642279 | Atipamezole hydrochloride crystallization method A method of isolating atipamezole hydrocloride as a crystalline salt is provided. ... | 01/05/2010 |
| 7592350 | Polycyclic compounds as potent alpha2-adrenoceptor antagonists A compound of formula I, wherein X, Z, R1 to R10, R15, R16, m, n, r and t are as defined in claim 1, or a pharmaceutically acceptable salt or ester thereo... | 09/22/2009 |
| 7115604 | Method for treating erectile dysfunction Levosimendan, or (−)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]propanedinitrile, which has been previously suggested for the treatment of congestive heart failure, is useful in the treatment of erectile dysfunction. ... | 10/03/2006 |
| 7485642 | Method for treating septic shock Levosimendan, or (−)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]propanedinitrile, which has been mentioned for the treatment of congestive heart failure, is useful in the treatment of septic shock. ... | 02/03/2009 |
| 7482340 | Pyridine derivatives useful for inhibiting sodium/calcium exchange system Therapeutically active compounds of formula (I) or (II): wherein the variables in formulas (I) and (II) are defined in the description, and pharmaceutically acceptable salts and esters thereof. The compounds are potent inhi... | 01/27/2009 |
| 7425568 | Compounds, which are potent inhibitors of Na /Ca exchange mechanism and are useful in the treatment of arrhythmias Therapeutically active compounds of formula (I): wherein the variables shown in formula (I) are defined in the disclosure; and pharmaceutically acceptable salts and esters thereof. The compounds are potent inhibitors of the... | 09/16/2008 |
| 7390923 | Propionamide derivatives useful as androgen receptor modulators Compounds of formula (I) wherein R1 to R4, X and A are as defined in the claims and pharmaceutically acceptable salts and esters thereof, are disclosed. The compounds of formula (I) possess utility as tissue-selective andro... | 06/24/2008 |
| 7368607 | Toremifene crystallization method The invention relates to a method for isolating toremifene from a mixture of toremifene and its corresponding E isomer. The method comprises contacting the isomer mixture with a first solvent comprising methanol, allowing toremifene to crystallize in said first solv... | 05/06/2008 |
| 7267813 | Inhalation particles incorporating a combination of two or more active ingredients Crystalline spherical inhalation particles incorporating a combination of two or more different active ingredients and a process for the preparation thereof. The particles have a narrow particle size distribution, rough surfaces and improved stability. The inhalatio... | 09/11/2007 |
| 7172752 | Combination particles for the treatment of asthma Inhalation particles incorporating, in an individual particle, a combination of a βhd 2-agonist and a glucocorticosteroid in a predetermined and constant ratio, a process for the preparation thereof and pharmaceutical compositions comprising the inhalation particle... | 02/06/2007 |
| 7173024 | Compounds having prolyl oligopeptidase inhibitory activity, methods for their preparation and their use Compounds of the formula (I), wherein the symbol aa means a residue of an α-amino acid. The invention is also directed to a method for the preparation of the compounds of formula (I), as well as their use as pro... | 02/06/2007 |
| 7045147 | Controlled release peroral compositions of levosimendan The invention relates to peroral pharmaceutical compositions which release levosimendan in a controlled fashion with reduced occurrence of undesired effects. Levosimendan, or (−)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]-hydrazono]propanedinitri... | 05/16/2006 |
| 6983748 | Dry powder inhaler A device for delivering a powdered medicament by inhalation comprises an air inlet passage having low pressure-drop and low turbulence for stabilizing air flow before aerosolization, a dosing cup in the region of reduced air velocity to delay aerosolization, a high ... | 01/10/2006 |
| 6951870 | Coumarin derivatives with COMT inhibiting activity Compounds of formula I′ wherein the two —OH substituents in the phenyl moiety are in a position ortho to one another and R1 in a position ortho to one of the hydroxy groups; and X, R1 to R... | 10/04/2005 |
| 6949548 | Combination therapy for the treatment of heart failure A combination therapy for the treatment of heart failure comprises administering a combination of levosimendan or a pharmaceutically acceptable salt thereof and a beta-adrenergic receptor antagonist to a patient. The combination synergistically reduces mortality in ... | 09/27/2005 |
| 6948495 | Powder inhaler An inhaler device comprising a container for powdered medicament, an inhalation channel, a movable metering member, a depressible actuator and a multiple dosage preventing means for locking the depressible actuator after use such that the actuator is unlocked only u... | 09/27/2005 |
| 6943164 | Pharmaceutical solutions of levosimendan Levosimendan solutions for pharmaceutical use, and particularly for intravenous administration. The solutions of the invention have enhanced stability and they are particularly useful as infusion or injection solutions or infusion concentrates. Levosimendan is usefu... | 09/13/2005 |
| 6926003 | Multidose powder inhaler A powder inhaler comprises a medicament container, a rotatable metering disc extending into the interior of the medicament container and an air channel through which air is drawn via a mouthpiece. The metering disc has one or more peripherally located dosing grooves... | 08/09/2005 |
| 6911209 | Method of treating sick sinus syndrome with levosimendan Levosimendan, or (−)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]propanedinitrile, which has been previously suggested for the treatment of congestive heart failure is useful in the treatment of sick sinus syndrome and/or sinoatrial condu... | 06/28/2005 |
| 6903114 | Derivatives of naphthalene with COMT inhibiting activity Compounds of formula (I′), wherein A, R1 to R3 and t are as defined in the disclosure, exhibit COMT enzyme inhibiting activity so that they are useful as COMT inhibitors. ... | 06/07/2005 |
| 6887888 | Soluble compositions of triphenylethylene antiestrogens Aqueous compositions of nonsteroidal triphenylethylene antiestrogens for pharmaceutical use comprising as a solubility enhancing agent a pharmaceutically acceptable mono- or dicarboxylic acid having 1-5 carbon atoms, wherein the carbon chain may further contain 1-4 ... | 05/03/2005 |
| 6886560 | Moisture protected powder inhaler A powder inhaler comprising a powder container, an air channel, a metering member equipped with a dosing recess, an actuating means for the displacement of the metering member between the filling and the inhalation position, and a closure element for plugging the ai... | 05/03/2005 |
| 6878702 | Anti-inflammatory agents The use of mitochondrial KATP channel openers, particularly compounds of general formula (I), for the treatment or prevention of inflammation by inducing apoptosis of inflammatory cells. ... | 04/12/2005 |
| 6846496 | Treatment of osteoporosis A method for the prevention or treatment of postmenopausal osteoporosis by initiating the treatment with a low close of an estrogenic compound and increasing the dose of the estrogenic compound after the initiation period. ... | 01/25/2005 |
| 6814072 | Powder inhaler A device for dispensing powdered medicament by inhalation comprises an axially movable metering rod (3) equipped with a dosing recess in the form of a hole (5). The metering rod (3) extends through the interior of the medicament container (1 | 11/09/2004 |
| 6797732 | Pharmaceutical composition comprising entracapone, levodopa, and carbidopa An oral solid fixed dose composition comprising pharmacologically effective amounts of entacapone, levodopa, and carbidopa, or pharmaceutically acceptable salts or hydrates thereof, and comprising at least one pharmaceutically acceptable excipient. The composition c... | 09/28/2004 |
| 6774103 | Compounds for deactivating phospholamban function on Ca-ATPase (phospholamban inhibitors) This invention relates to determining the three-dimensional structure of the cytosolic domain of phospholamban (PLB) and its active site from NMR data of sufficiently high resolution for the three-dimensional structure determination. The invention also relates to me... | 08/10/2004 |
| 6769601 | Inhaler with a dose counter A multiple-dose powder inhaler comprising an inhaler body defining a medicament container, an air channel, a mouthpiece, a rotatable metering drum with one or more peripheral dosing recesses and a dose counter for indicating the number of metered doses of medicament... | 08/03/2004 |
| 6730673 | Pharmaceutical solutions of levosimendan Levosimendan solutions for pharmaceutical use, and particularly for intravenous administration. The solutions of the invention have enhanced stability and they are particularly useful as infusion or injection solutions or infusion concentrates. Levosimendan is usefu... | 05/04/2004 |
| 6723754 | Use of COMT inhibitors as analgesics The use of COMT inhibitors in the treatment of control of pain in mammals, for example in animals and humans. ... | 04/20/2004 |
| 6716867 | Use of dexmedetomidine for ICU sedation The present invention relates to a method of sedating a patient while in the intensive care unit comprising administering dexmedetomidine of a pharmaceutically acceptable salt thereof to the patient, wherein the patient remains arousable and orientated. ... | 04/06/2004 |
| 6699868 | Pyridazinyl phenyl hydrazones useful against congestive heart failure Therapeutically active compounds of formula (I): ##STR1## in which R1 to R4 means hydrogen, alkyl, alkenyl, aryl, arylalkyl, carboxyalkyl, hydroxyalkyl or halogenalkyl, or R2 and R3 form a ring of 5-7 carbon... | 03/02/2004 |
| 6632841 | Soluble compositions of triphenylethylene antiestrogens Aqueous compositions of nonsteroidal triphenylethylene antiestrogens for pharmaceutical use comprising as a solubility enhancing agent a pharmaceutically acceptable mono- or dicarboxylic acid having 1-5 carbon atoms, wherein the carbon chain may further c... | 10/14/2003 |
| 6624201 | HIGH PURITY (1R,2S,4R)-(-)-2-[(2'-{N,N-DIMETHYLAMINO}-ETHOXY)]-2-[PHENYL]-1,7,7 -TRI-[METHYL]-BICYCLO [2.2.1]HEPTANE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALTS THEREOF AND A PROCESS FOR THE PREPARATION OF THESE COMPOUNDS AS WELL AS MEDICAMENTS CONTAINING 1 OR MORE OF THESE COMPOUNDS AND THEIR USE The invention relates to high purity (1R,2S,4R)-(-)-2-[(2'-{N,N-dimethylamino}-ethoxy)]-2-[phenyl]-1,7,7-tri-[m ethyl]-bicyclo[2.2.1]heptane and pharmaceutically acceptable acid addition salts thereof containing not more than 0.2% of (1R,3S,4R)-3-[(2'... | 09/23/2003 |
